Novartis Ag (NVS) Total Debt (2009 - 2025)
Novartis Ag's (NVS) quarterly Total Debt came in at $28.7 billion in Q4 2025, up 30.54% year-on-year from $22.0 billion in Q4 2024, and down 6.68% quarter-over-quarter from $30.8 billion in Q2 2025.
Novartis Ag (NVS) Total Debt (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Total Debt across 13 years of filings, most recently posting $28.7 billion for Q4 2025.
- Total Debt for Q4 2025 came in at $28.7 billion, up 30.54% year-over-year; the trailing twelve-month figure through Dec 2025 was $28.7 billion (up 30.54% YoY), and the FY2025 annual result was $28.7 billion, up 30.54% from the prior year.
- Total Debt came in at $28.7 billion for Q4 2025 at Novartis Ag, down from $30.8 billion in the prior quarter.
- In the past five years, Total Debt ranged from a high of $33.9 billion in Q2 2021 to a low of $19.1 billion in Q4 2023.
- The 5-year median for Total Debt is $28.0 billion (2024), against an average of $27.3 billion.
- Across the five-year window, Total Debt dropped 27.18% in 2023 and soared 30.54% in 2025, its largest moves.
- Novartis Ag's Total Debt stood at $29.2 billion in 2021, then declined by 10.35% to $26.2 billion in 2022, then decreased by 27.18% to $19.1 billion in 2023, then advanced by 15.47% to $22.0 billion in 2024, then jumped by 30.54% to $28.7 billion in 2025.
- The last three Total Debt figures came in at $28.7 billion (Q4 2025), $30.8 billion (Q2 2025), and $22.0 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 43.37 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 54.99 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 44.46 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.73 Bn |
| Jun 30, 2025 | 30.78 Bn |
| Dec 31, 2024 | 22.01 Bn |
| Jun 30, 2024 | 27.20 Bn |
| Dec 31, 2023 | 19.06 Bn |
| Jun 30, 2023 | 26.55 Bn |
| Dec 31, 2022 | 26.18 Bn |
| Jun 30, 2022 | 29.28 Bn |
| Dec 31, 2021 | 29.20 Bn |
| Jun 30, 2021 | 33.90 Bn |
| Dec 31, 2020 | 28.53 Bn |
| Jun 30, 2020 | 32.83 Bn |
| Dec 31, 2019 | 21.07 Bn |
| Jun 30, 2019 | 28.22 Bn |
| Mar 31, 2019 | 338.00 Mn |
| Dec 31, 2018 | 23.17 Bn |
| Jun 30, 2018 | 32.36 Bn |
| Dec 31, 2017 | 23.92 Bn |
| Sep 30, 2017 | -80.00 Mn |
| Jun 30, 2017 | -105.00 Mn |